Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 529-534

  Banz, Kurt ^a   Bischoff, Helge ^b   Brunner, Matthias ^a   Chouaid, Christos ^c   de Castro Carpeño, Javier ^d   de Marinis, Filippo ^e   Grossi, Francesco ^f   Vergnenègre, Alain ^g   Walzer, Stefan ^h  

^a Outcomes International   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HÔPITAL SAINT ANTOINE   (France)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Adverse events; Costs; Erlotinib; Indirect comparison; Maintenance therapy; NSCLC; Pemetrexed

Indexed keywords

ERLOTINIB; PEMETREXED;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG TOLERABILITY; ECONOMIC ASPECT; FATIGUE; FRANCE; GERMANY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFECTION; ITALY; LENGTH OF STAY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; SENSORY NEUROPATHY; SPAIN; STOMATITIS; VOMITING;

CARCINOMA, NON-SMALL-CELL LUNG; FRANCE; GERMANY; GLUTAMATES; GUANINE; ITALY; QUINAZOLINES; SPAIN;

EID: 80755138389     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.010     Document Type: Article

References (17)

1. World Health Organization, Fact sheet No. 297, February 2009. Available from: [accessed 23.06.10]. http://www.who.int/mediacentre/factsheets/fs297/en/index.html.
2. GLOBOCAN 2008, International Agency for Research of Cancer, Lyon, France. Available from: [accessed 23.06.10]. http://globocan.iarc.fr/.
3. Navada S., Lai P., Schwartz A.G., Kalemkerian G.P. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database. J Clin Oncol 2006, 24(Suppl. 18S):384S. [abstract 7082].
4. Sher T., Dy G.K., Adjei A.A. Small cell lung cancer. Mayo Clin Proc 2008, 83:355-367.
5. Brodowicz T., Krzakowski M., Zwitter M., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163.
6. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
7. Fidias P.M., Dakhil S.R., Lyss A.P., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
8. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
9. Shih C., Chen V.J., Gossett L.S., et al. LY23 a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57:1116-1123.
10. Ojeda B., de Sande L.M., Casado A., et al. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer 2003, 89(6):1002-1007.
11. Ihbe-Heffinger A., Paessens B., von Schilling C., et al. Cost analysis of febrile neutropenia (FN) management in three tumour types in Germany. J Clin Oncol 2008, 26(Suppl.). [abstract 20651].
12. National Cancer Institute. Common toxicity criteria (NCI-CTC) V3.0. Available from: [accessed 10.02.10]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
13. Learn P.A., Bach P.B. Pem and the cost of multicycle maintenance. J Thorac Oncol 2010, 5(8):1111-1112.
14. Casciano R., Bischoff H., Nuijten M., et al. Maintenance erlotinib versus pemetrexed for the treatment of non-small cell lung cancer: indirect comparison applying real-life outcomes. Value Health 2010, 7:A254. [abstract PCN20].
15. Perol M., Chouaid C., Milleron B.J., et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010, 28(Suppl. 15). [abstract 7507].
16. Mickisch G., Gore M., Escudier B., et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010, 102:80-86.
17. Brown B., Diamantopoulos A., Bernier J., et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy Switzerland, and the United Kingdom. Value Health 2008, 5:791-799.